Role of the Lyn tyrosine kinase in the development of autoimmune disease

International Journal of Clinical Rheumatology

Volumn 9, Issue 5, 2014, Pages 519-535

  Tsantikos, Evelyn ^a   Gottschalk, Timothy A ^a   Maxwell, Mhairi J ^a   Hibbs, Margaret L ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

autoimmune disease; glomerulonephritis; inflammation; lupus; Lyn

Indexed keywords

B LYMPHOCYTE RECEPTOR; BAFETINIB; BOSUTINIB; DASATINIB; ENZYME ACTIVATOR; MLR 1023; PROTEIN KINASE LYN; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC MODEL; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATION; LEUKEMIA; NONHUMAN; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FAMILY; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TH2 CELL;

EID: 84913592716     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.14.44     Document Type: Review

References (106)

1. Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim. Biophys. Acta 1784(1), 56-65 (2008).
2. Yamanashi Y, Fukushige S, Semba K et al. The yes-related cellular gene lyn encodes a possible tyrosine kinase similar to p56lck. Mol. Cell. Biol. 7(1), 237-243 (1987).
3. Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241(4861), 42-52 (1988).
4. Hibbs ML, Stanley E, Maglitto R, Dunn AR. Identification of a duplication of the mouse Lyn gene. Gene 156, 175-181 (1995).
5. Yi T, Bolen JB, Ihle JN. Hematopoietic cells express two forms of lyn kinase differing by 21 amino acids in the amino terminus. Mol. Cell. Biol. 11(5), 2391-2398 (1991).
6. Stanley E, Ralph S, Mcewen S et al. Alternatively spliced murine lyn mRNAs encode distinct proteins. Mol. Cell. Biol. 11(7), 3399-3406 (1991).
7. Rider LG, Raben N, Miller L, Jelsema C. The cDNAs encoding two forms of the LYN protein tyrosine kinase are expressed in rat mast cells and human myeloid cells. Gene 138(1-2), 219-222 (1994).
8. Alvarez-Errico D, Yamashita Y, Suzuki R et al. Functional analysis of Lyn kinase A and B isoforms reveals redundant and distinct roles in Fc epsilon RI-dependent mast cell activation. J. Immunol. 184(9), 5000-5008 (2010).
9. Beavitt SJ, Harder KW, Kemp JM et al. Lyn-deficient mice develop severe, persistent asthma: Lyn is a critical negative regulator of Th2 immunity. J. Immunol. 175(3), 1867-1875 (2005).
10. Yamanashi Y, Mori S, Yoshida M et al. Selective expression of a protein-tyrosine kinase, p56 lyn, in hematopoietic cells and association with production of human T-cell lymphotropic virus type I. Proc. Natl Acad. Sci. USA 86, 6538-6542 (1989).
11. O'connor R, Torigoe T, Reed JC, Santoli D. Phenotypic changes induced by interleukin-2 (IL-2) and IL-3 in an immature T-lymphocytic leukemia are associated with regulated expression of IL-2 receptor beta chain and of protein tyrosine kinases LCK and LYN. Blood 80, 1017-1025 (1992).
12. Uchiumi F, Semba K, Yamanashi Y et al. Characterization of the promoter region of the Src family gene Lyn and its transactivation by human T-cell leukemia virus type I-encoded p40tax. Mol. Cell. Biol. 12(9), 3784-3795 (1992).
13. Buss JE, Sefton BM. Myristic acid, a rare fatty acid, is the lipid attached to the transforming protein of Rous sarcoma virus and its cellular homolog. J. Virol. 53(1), 7-12 (1985).
14. Latour S, Veillette A. Proximal protein tyrosine kinases in immunoreceptor signaling. Curr. Opin. Immunol. 13, 299-306 (2001).
15. Fitzer-Attas CJ, Lowry M, Crowley MT et al. Fcgamma receptor-mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn. J. Exp. Med. 191(4), 669-682 (2000).
16. Campbell MA, Sefton BM. Association between B-lymphocyte membrane immunoglobulin and multiple members of the Src family of protein tyrosine kinases. Mol. Cell. Biol. 12, 2315-2321 (1992).
17. Yamamoto T, Yamanashi Y, Toyoshima K. Association of Srcfamily kinase Lyn with B-cell antigen receptor. Immunol. Rev. 132, 187-206 (1993).
18. Hibbs ML, Tarlinton DM, Armes J et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 83, 301-311 (1995).
19. Nishizumi H, Taniuchi I, Yamanashi Y et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in Lyn-deficient mice. Immunity 3, 549-560 (1995).
20. Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM. Lyn tyrosine kinase; accentuating the positive and the negative. Immunity 22(1), 9-18 (2005).
21. Okada M, Nakagawa H. Identification of a novel protein tyrosine kinase that phosphorylates pp60c-src and regulates its activity in neonatal rat brain. Biochem. Biophys. Res. Commun. 154(2), 796-802 (1988).
22. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim. Biophys. Acta 1287(2-3), 121-149 (1996).
23. Yanagi S, Sugawara H, Kurosaki M, Sabe H, Yamamura H, Kurosaki T. CD45 modulates phosphorylation of both autophosphorylation and negative regulatory tyrosines of Lyn in B cells. J. Biol. Chem. 271(48), 30487-30492 (1996).
24. Katagiri T, Ogimoto M, Hasegawa K, Mizuno K, Yakura H. Selective regulation of Lyn tyrosine kinase by CD45 in immature B cells. J. Biol. Chem. 270(47), 27987-27990 (1995).
25. Somani AK, Yuen K, Xu F, Zhang J, Branch DR, Siminovitch KA. The SH2 domain containing tyrosine phosphatase-1 down-regulates activation of Lyn and Lyninduced tyrosine phosphorylation of the CD19 receptor in B cells. J. Biol. Chem. 276(3), 1938-1944 (2001).
26. Harder KW, Parsons LM, Armes J et al. Gain-and loss-offunction Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity 15(4), 603-615 (2001).
27. Hibbs ML, Harder KW, Armes J et al. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J. Exp. Med. 196(12), 1593-1604 (2002).
28. Williams NK, Lucet IS, Klinken SP, Ingley E, Rossjohn J. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo-and inhibitor-bound state. J. Biol. Chem. 284(1), 284-291 (2009).
29. Burkhardt AL, Brunswick M, Bolen JB, Mond JJ. Antiimmunoglobulin stimulation of B lymphocytes activates src-related protein-tyrosine kinases. Proc. Natl Acad. Sci. USA 88, 7410-7414 (1991).
30. Yamanashi Y, Kakiuchi T, Mizuguchi J, Yamamoto T, Toyoshima K. Association of B cell antigen receptor with protein tyrosine kinase Lyn. Science 251, 192-194 (1991).
31. Yamanashi Y, Fukui Y, Wongsasant B et al. Activation of Src-like protein-tyrosine kinase Lyn and its association with phosphatidylinositol 3-kinase upon B-cell antigen receptormediated signaling. Proc. Natl Acad. Sci. USA 89, 1118-1122 (1992).
32. Saouaf SJ, Mahajan S, Rowley RB et al. Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement. Proc. Natl Acad. Sci. USA 91(20), 9524-9528 (1994).
33. Schmitz R, Baumann G, Gram H. Catalytic specificity of phosphotyrosine kinases Blk, Lyn, c-Src and Syk as assessed by phage display. J. Mol. Biol. 260(5), 664-677 (1996).
34. Pleiman CM, Hertz WM, Cambier JC. Activation of phosphatidylinositol-3' kinase by Src-family kinase SH3 binding to the p85 subunit. Science 263(5153), 1609-1612 (1994).
35. Horikawa K, Nishizumi H, Umemori H, Aizawa S, Takatsu K, Yamamoto T. Distinctive roles of Fyn and Lyn in IgD-and IgM-mediated signaling. Int. Immunol. 11(9), 1441-1449 (1999).
36. Cornall RJ, Cyster JG, Hibbs ML et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 8(4), 497-508 (1998).
37. Chan VWF, Meng F, Soriano P, Defranco AL, Lowell CA. Characterization of the B lymphocyte populations in Lyn deficient mice and the role of Lyn in signal initiation and down regulation. Immunity 7, 69-81 (1997).
38. Chan VWF, Lowell CA, Defranco AL. Defective negative regulation of antigen receptor signaling in Lyn-deficient B lymphocytes. Curr. Biol. 8(10), 545-553 (1998).
39. Ho LH, Uehara T, Chen CC, Kubagawa H, Cooper MD. Constitutive tyrosine phosphorylation of the inhibitory paired Ig-like receptor PIR-B. Proc. Natl Acad. Sci. USA 96(26), 15086-15090 (1999).
40. Smith KGC, Tarlinton DM, Doody GM, Hibbs ML, Fearon DT. Inhibition of the B cell by CD22: a requirement for Lyn. J. Exp. Med. 187(5), 807-811 (1998).
41. Nishizumi H, Horikawa K, Mlinaric-Rascan I, Yamamoto T. A double-edged kinase Lyn: a positive and negative regulator for antigen receptor-mediated signals. J. Exp. Med. 187(8), 1343-1348 (1998).
42. Ono M, Bolland S, Tempst P, Ravetch JV. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 383(6597), 263-266 (1996).
43. Maeda A, Scharenberg AM, Tsukada S, Bolen JB, Kinet JP, Kurosaki T. Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1. Oncogene 18(14), 2291-2297 (1999).
44. Harder KW, Quilici C, Naik E et al. Perturbed myelo/ erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1. Blood 104(13), 3901-3910 (2004).
45. Ono M, Okada H, Bolland S, Yanagi S, Kurosaki T, Ravetch JV. Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling. Cell 90(2), 293-301 (1997).
46. Blery M, Kubagawa H, Chen CC, Vely F, Cooper MD, Vivier E. The paired Ig-like receptor PIR-B is an inhibitory receptor that recruits the protein-tyrosine phosphatase SHP-1. Proc. Natl Acad. Sci. USA 95(5), 2446-2451 (1998).
47. Chu CL, Lowell CA. The Lyn tyrosine kinase differentially regulates dendritic cell generation and maturation. J. Immunol. 175(5), 2880-2889 (2005).
48. Odom S, Gomez G, Kovarova M et al. Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase. J. Exp. Med. 199(11), 1491-1502 (2004).
49. Hernandez-Hansen V, Bard JD, Tarleton CA et al. Increased expression of genes linked to FcepsilonRI signaling and to cytokine and chemokine production in Lyn-deficient mast cells. J. Immunol. 175(12), 7880-7888 (2005).
50. Crowley MT, Costello PS, Fitzer-Attas CJ et al. A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages. J. Exp. Med. 186(7), 1027-1039 (1997).
51. Tsantikos E, Oracki SA, Quilici C, Anderson GP, Tarlinton DM, Hibbs ML. Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6. J. Immunol. 184(3), 1348-1360 (2010).
52. Lau M, Tsantikos E, Maxwell MJ, Tarlinton DM, Anderson GP, Hibbs ML. Loss of STAT6 promotes autoimmune disease and atopy on a susceptible genetic background. J. Autoimmun. 39(4), 388-397 (2012).
53. Oracki SA, Tsantikos E, Quilici C et al. CTLA4Ig alters the course of autoimmune disease development in Lyn-/-mice. J. Immunol. 184(2), 757-763 (2010).
54. Tsantikos E, Quilici C, Harder KW et al. Perturbation of the CD4 T cell compartment and expansion of regulatory T cells in autoimmune-prone Lyn-deficient mice. J. Immunol. 183(4), 2484-2494 (2009).
55. Tsantikos E, Maxwell MJ, Putoczki T et al. Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice. Arthritis Rheum. 65(10), 2691-2702 (2013).
56. Calero I, Sanz I. Targeting B cells for the treatment of SLE. The beginning of the end or the end of the beginning? Discov. Med. 10(54), 416-424 (2010).
57. Mosak J, Furie R. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy. Lupus 22(4), 361-371 (2013).
58. Stohl W. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Exp. Opin. Ther. Targets 18(4), 473-489 (2014).
59. Anolik JH. B cell biology and dysfunction in SLE. Bull. NYU Hosp. Jt. Dis. 65(3), 182-186 (2007).
60. Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J. Clin. Invest. 98(11), 2549-2557 (1996).
61. Liossis SNC, Solomou EE, Dimopoulos MA, Panayiotidis P, Mavrikakis MM, Sfikakis PP. B-cell kinase Lyn deficiency in patients with systemic lupus erythematosus. J. Invest. Med. 49(2), 157-165 (2001).
62. Huck S, Le Corre R, Youinou P, Zouali M. Expression of B cell receptor-associated signaling molecules in human lupus. Autoimmunity 33, 213-224 (2001).
63. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA. Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum. 52(12), 3955-3965 (2005).
64. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA. Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum. 56(1), 291-302 (2007).
65. Karampetsou MP, Andonopoulos AP, Liossis SN. Treatment with TNFalpha blockers induces phenotypical and functional aberrations in peripheral B cells. Clin. Immunol. 140(1), 8-17 (2011).
66. Harley JB, Alarcon-Riquelme ME, Criswell LA et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40(2), 204-210 (2008).
67. Lu R, Vidal GS, Kelly JA et al. Genetic associations of LYN with systemic lupus erythematosus. Genes Immun. 10(5), 397-403 (2009).
68. Jarvinen TM, Hellquist A, Zucchelli M et al. Replication of GWAS-identified systemic lupus erythematosus susceptibility genes affirms B-cell receptor pathway signalling and strengthens the role of IRF5 in disease susceptibility in a Northern European population. Rheumatology 51(1), 87-92 (2012).
69. Manjarrez-Orduno N, Marasco E, Chung SA et al. CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation. Nat. Genet. 44(11), 1227-1230 (2012).
70. Wu H, Cantor RM, Graham DS et al. Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. Arthritis Rheum. 52(8), 2396-2402 (2005).
71. Lee YH, Rho YH, Choi SJ et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases-a meta-analysis. Rheumatology 46(1), 49-56 (2007).
72. Yuasa T, Kubo S, Yoshino T et al. Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collageninduced arthritis. J. Exp. Med. 189(1), 187-194 (1999).
73. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13(2), 277-285 (2000).
74. Kyogoku C, Dijstelbloem HM, Tsuchiya N et al. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. 46(5), 1242-1254 (2002).
75. Su K, Li X, Edberg JC, Wu J, Ferguson P, Kimberly RP. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor expression and function. J. Immunol. 172(11), 7192-7199 (2004).
76. Tsantikos E, Maxwell MJ, Kountouri N, Harder KW, Tarlinton DM, Hibbs ML. Genetic interdependence of Lyn and negative regulators of B cell receptor signaling in autoimmune disease development. J. Immunol. 189(4), 1726-1736 (2012).
77. Hasegawa M, Fujimoto M, Poe JC, Steeber DA, Lowell CA, Tedder TF. A CD19-dependent signaling pathway regulates autoimmunity in Lyn-deficient mice. J. Immunol. 167(5), 2469-2478 (2001).
78. Satterthwaite AB, Lowell CA, Khan WN, Sideras P, Alt FW, Witte ON. Independent and opposing roles for Btk and Lyn in B and myeloid signaling pathways. J. Exp. Med. 188(5), 833-844 (1998).
79. Takeshita H, Taniuchi I, Kato J, Watanabe T. Abrogation of autoimmune disease in Lyn-deficient mice by the mutation of the Btk gene. Int. Immunol. 10(4), 435-444 (1998).
80. Whyburn LR, Halcomb KE, Contreras CM, Lowell CA, Witte ON, Satterthwaite AB. Reduced dosage of Bruton's tyrosine kinase uncouples B cell hyperresponsiveness from autoimmunity in lyn-/-mice. J. Immunol. 171(4), 1850-1858 (2003).
81. Gutierrez T, Halcomb KE, Coughran AJ, Li QZ, Satterthwaite AB. Separate checkpoints regulate splenic plasma cell accumulation and IgG autoantibody production in Lyndeficient mice. Eur. J. Immunol. 40(7), 1897-1905 (2010).
82. Verhagen AM, Wallace ME, Goradia A et al. A kinasedead allele of Lyn attenuates autoimmune disease normally associated with Lyn deficiency. J. Immunol. 182(4), 2020-2029 (2009).
83. Barouch-Bentov R, Che J, Lee CC et al. A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Mol. Cell 33(1), 43-52 (2009).
84. Marchetti S, Gamas P, Belhacene N et al. The caspase-cleaved form of LYN mediates a psoriasis-like inflammatory syndrome in mice. EMBO J. 28(16), 2449-2460 (2009).
85. Charles N, Hardwick D, Daugas E, Illei GG, Rivera J. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat. Med. 16(6), 701-707 (2010).
86. Maxwell MJ, Tsantikos E, Kong AM, Vanhaesebroeck B, Tarlinton DM, Hibbs ML. Attenuation of phosphoinositide 3-kinase delta signaling restrains autoimmune disease. J. Autoimmun. 38(4), 381-391 (2012).
87. Gutierrez T, Mayeux JM, Ortega SB et al. IL-21 promotes the production of anti-DNA IgG but is dispensable for kidney damage in Lyn-/-mice. Eur. J. Immunol. 43(2), 382-393 (2013).
88. Hua Z, Gross AJ, Lamagna C et al. Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. J. Immunol. 192(3), 875-885 (2014).
89. Yu CC, Yen TS, Lowell CA, Defranco AL. Lupus-like kidney disease in mice deficient in the Src family tyrosine kinases Lyn and Fyn. Curr. Biol. 11(1), 34-38 (2001).
90. Saijo K, Schmedt C, Su IH et al. Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development. Nat. Immunol. 4(3), 274-279 (2003).
91. Scapini P, Hu Y, Chu CL et al. Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice. J. Exp. Med. 207(8), 1757-1773 (2010).
92. Moon BG, Takaki S, Nishizumi H, Yamamoto T, Takatsu K. Abrogation of autoimmune disease in Lyn-deficient mice by the deletion of IL-5 receptor alpha chain gene. Cell. Immunol. 228(2), 110-118 (2004).
93. Scapini P, Lamagna C, Hu Y et al. B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice. Proc. Natl Acad. Sci. USA 108(41), E823-E832 (2011).
94. Silver KL, Crockford TL, Bouriez-Jones T, Milling S, Lambe T, Cornall RJ. MyD88-dependent autoimmune disease in Lyn-deficient mice. Eur. J. Immunol. 37(10), 2734-2743 (2007).
95. Lamagna C, Scapini P, Van Ziffle JA, Defranco AL, Lowell CA. Hyperactivated MyD88 signaling in dendritic cells, through specific deletion of Lyn kinase, causes severe autoimmunity and inflammation. Proc. Natl Acad. Sci. USA 110(35), E3311-E3320 (2013).
96. Lamagna C, Hu Y, Defranco AL, Lowell CA. B cell-specific loss of Lyn kinase leads to autoimmunity. J. Immunol. 192(3), 919-928 (2014).
97. Bygrave AE, Rose KL, Cortes-Hernandez J et al. Spontaneous autoimmunity in 129 and C57BL/6 miceimplications for autoimmunity described in gene-targeted mice. PLoS Biol. 2(8), E243 (2004).
98. Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat. Rev. Drug Rev. 13(5), 379-395 (2014).
99. Texido G, Su IH, Mecklenbrauker I et al. The B-cell-specific Src-family kinase Blk is dispensable for B-cell development and activation. Mol. Cell. Biol. 20(4), 1227-1233 (2000).
100. Luciano F, Herrant M, Jacquel A, Ricci JE, Auberger P. The p54 cleaved form of the tyrosine kinase Lyn generated by caspases during BCR-induced cell death in B lymphoma acts as a negative regulator of apoptosis. FASEB J. 17(6), 711-713 (2003).
101. Deguchi Y, Kimura S, Ashihara E et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinibresistant cell lines. Leukemia Res. 32(6), 980-983 (2008).
102. Puttini M, Coluccia AM, Boschelli F et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 66(23), 11314-11322 (2006).
103. ClinicalTrials.gov database. http://clinicaltrials.gov/
104. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7(5), 345-356 (2007).
105. Saporito MS, Ochman AR, Lipinski CA, Handler JA, Reaume AG. MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo. J. Pharmacol. Exp. Ther. 342(1), 15-22 (2012).
106. Ochman AR, Lipinski CA, Handler JA, Reaume AG, Saporito MS. The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of Type 2 diabetes. J. Pharmacol. Exp. Ther. 342(1), 23-32 (2012).